Regeneron Expands its Existing Collaboration with HHS'BARDA to Develop Antibody Therapies for Coronavirus
Shots:
- The collaboration leverages Regeneron's VelociSuite technologies including the VelocImmune platform to develop mAb as monothx. or in combination to treat coronavirus (2019-nCoV)
- In 2017- HHS and Regeneron collaborated for discovery- research- development and manufacturing of an Abs targeting up to 10 pathogens including influenza virus and 2019-nCoV
- Regeneron's VelociSuite technologies including the VelocImmune platform utilizes a unique genetically engineered mouse with a humanized immune system- accelerating swift identification- preclinical validation and development Ab therapies
Click here to read full press release/ article | Ref: Regeneron | Image: The Pharma Letter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com